Published in Cancer Treat Rep on June 01, 1979
Molecular cloning, sequencing and expression studies of the human breast cancer cell glutaminase. Biochem J (2000) 1.34
The Cremeomycin Biosynthetic Gene Cluster Encodes a Pathway for Diazo Formation. Chembiochem (2015) 0.86
Glutaminolysis and autophagy in cancer. Autophagy (2015) 0.86
Reviving Lonidamine and 6-Diazo-5-oxo-L-norleucine to Be Used in Combination for Metabolic Cancer Therapy. Biomed Res Int (2015) 0.85
Inhibition of mitochondrial glutaminase activity reverses acquired erlotinib resistance in non-small cell lung cancer. Oncotarget (2016) 0.84
Feasibility and antitumor efficacy in vivo, of simultaneously targeting glycolysis, glutaminolysis and fatty acid synthesis using lonidamine, 6-diazo-5-oxo-L-norleucine and orlistat in colon cancer. Oncol Lett (2017) 0.75
Glutamine deprivation plus BPTES alters etoposide- and cisplatin-induced apoptosis in triple negative breast cancer cells. Oncotarget (2016) 0.75
Therapeutic Targeting of Epithelial Plasticity Programs: Focus on the Epithelial-Mesenchymal Transition. Cells Tissues Organs (2017) 0.75
Structural basis for exploring the allosteric inhibition of human kidney type glutaminase. Oncotarget (2016) 0.75
Heteroatom-Heteroatom Bond Formation in Natural Product Biosynthesis. Chem Rev (2017) 0.75
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol (1997) 29.02
Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med (1979) 6.00
Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol (2001) 5.17
A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol (1996) 4.07
Hypersensitivity reactions from taxol. J Clin Oncol (1990) 3.83
ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med (1997) 3.64
Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res (1994) 3.30
Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction. Proc Natl Acad Sci U S A (1990) 3.03
Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families. Am J Hum Genet (1997) 2.31
Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study. J Clin Oncol (1995) 2.26
High frequency of BRCA1 and BRCA2 germline mutations in Ashkenazi Jewish ovarian cancer patients, regardless of family history. Gynecol Oncol (1997) 2.25
No evidence of acute cardiovascular complications of chemotherapy for testicular cancer: an analysis of the Testicular Cancer Intergroup Study. J Clin Oncol (1992) 2.11
A single nucleotide polymorphism in the RAD51 gene modifies cancer risk in BRCA2 but not BRCA1 carriers. Proc Natl Acad Sci U S A (2001) 2.09
Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development. J Clin Oncol (1999) 2.00
Toxic effects of cis-dichlorodiammineplatinum(II) in man. Cancer Treat Rep (1980) 1.99
Association between human tumor colony-forming assay results and response of an individual patient's tumor to chemotherapy. Am J Med (1981) 1.92
Double minute chromosomes can be produced from precursors derived from a chromosomal deletion. Mol Cell Biol (1988) 1.81
Enhancement of antitumor activity of alkylating agents by the radiation sensitizer misonidazole. Cancer Res (1980) 1.78
Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies. J Clin Oncol (1995) 1.77
Pleural mesothelioma: clinical features and therapeutic implications. Ann Intern Med (1977) 1.70
G-quadruplexes as targets for drug design. Pharmacol Ther (2000) 1.63
Effects of cationic porphyrins as G-quadruplex interactive agents in human tumor cells. Cancer Res (1999) 1.63
Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions. Ann Oncol (2003) 1.63
Duration of empiric antibiotic therapy in granulocytopenic patients with cancer. Am J Med (1979) 1.61
A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin Cancer Res (2000) 1.59
Characterization of an episome produced in hamster cells that amplify a transfected CAD gene at high frequency: functional evidence for a mammalian replication origin. Mol Cell Biol (1987) 1.58
Transforming growth factor beta: potential autocrine growth inhibitor of estrogen receptor-negative human breast cancer cells. Cancer Res (1988) 1.57
Clinical studies with 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (NSC 79037). Cancer Res (1971) 1.57
Phase I and pharmacologic study of the specific matrix metalloproteinase inhibitor BAY 12-9566 on a protracted oral daily dosing schedule in patients with solid malignancies. J Clin Oncol (2000) 1.57
Phase I and pharmacologic study of the tyrosine kinase inhibitor SU101 in patients with advanced solid tumors. J Clin Oncol (1999) 1.56
A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin) Clin Cancer Res (1999) 1.54
The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. Gastrointestinal Tumor Study Group. J Clin Oncol (1989) 1.53
Proteasome inhibition with bortezomib (PS-341): a phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycle. J Clin Oncol (2005) 1.50
Diagnostic reliability of needle biopsy of the parietal pleura. A review of 272 biopsies. Am J Clin Pathol (1975) 1.48
Hormonal therapy of breast cancer: new approaches and concepts. Ann Intern Med (1978) 1.48
Staging relationships and outcome in early stage testicular cancer: a report from the Testicular Cancer Intergroup Study. J Urol (1991) 1.47
Treatment of breast cancer with medroxyprogesterone acetate. Ann Intern Med (1968) 1.45
Prospective clinical trial of a human tumor cloning system. Cancer Res (1983) 1.44
A phase I clinical and pharmacokinetic study of the angiogenesis inhibitor, tecogalan sodium. Ann Oncol (1996) 1.43
Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases. Am J Med (1977) 1.42
A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma. Cancer (1999) 1.41
Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol (1996) 1.41
Severe neurotoxicity from vinorelbine-paclitaxel combinations. J Natl Cancer Inst (1996) 1.40
Cis-diamminedichloroplatinum (II). A new anticancer drug. Ann Intern Med (1977) 1.40
A method for the evaluation of dose-toxicity relationships in clinical trials. Stat Med (1989) 1.39
Ability of circular extrachromosomal DNA molecules to carry amplified MYCN proto-oncogenes in human neuroblastomas in vivo. J Natl Cancer Inst (1990) 1.38
Defining alternative medicine. Isr Med Assoc J (2002) 1.38
L-asparaginase pharmacokinetics and asparagine levels in cerebrospinal fluid of rhesus monkeys and humans. Cancer Res (1981) 1.34
Clinical correlates of MDR1 (P-glycoprotein) gene expression in ovarian and small-cell lung carcinomas. J Natl Cancer Inst (1992) 1.33
A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation. Cancer Chemother Pharmacol (1999) 1.32
Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study. J Natl Cancer Inst (1998) 1.32
Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies. Cancer Chemother Rep (1972) 1.32
Immediate adjuvant chemotherapy versus observation with treatment at relapse in pathological stage II testicular cancer. N Engl J Med (1987) 1.30
Tumor lysis syndrome in nonhematologic malignancies. Report of a case and review of the literature. Am J Clin Oncol (1994) 1.22
Selection of cancer chemotherapy for a patient by an in vitro assay versus a clinician. J Natl Cancer Inst (1990) 1.22
Phase II trial of docetaxel in patients with advanced cutaneous malignant melanoma previously untreated with chemotherapy. J Clin Oncol (1995) 1.20
Two-stage plans for patient accrual in phase II cancer clinical trials. Cancer Treat Rep (1980) 1.19
Cytotoxic drug-induced pulmonary disease: update 1980. Am J Med (1980) 1.18
Bone-marrow examination in 100 consecutive patients with bronchogenic carcinoma. Lancet (1971) 1.18
Lung cancer: diagnosis in metastatic sites. Semin Oncol (1974) 1.17
Taxol: a new and effective anti-cancer drug. Anticancer Drugs (1991) 1.17
"Send this patient's tumor for culture and sensitivity". N Engl J Med (1983) 1.17
Methodology for the assessment of new dichotomous diagnostic tests. J Chronic Dis (1981) 1.16
Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro. J Natl Cancer Inst (1992) 1.16
The cardiotoxicity of anticancer agents. Semin Oncol (1982) 1.15
cis-Dichlorodiammineplatinum(II) for the treatment of advanced ovarian cancer. Cancer Treat Rep (1980) 1.15
Platinum-DNA adduct in leukocyte DNA of a cohort of 49 patients with 24 different types of malignancies. Cancer Res (1993) 1.15
Phase I clinical trial of gemcitabine given as an intravenous bolus on 5 consecutive days. Eur J Cancer (1994) 1.15
Phase I study of (6R)-5,10-dideazatetrahydrofolate: a folate antimetabolite inhibitory to de novo purine synthesis. J Natl Cancer Inst (1993) 1.15
Efficacy of 6-diazo-5-oxo-L-norleucine and N-[N-gamma-glutamyl-6-diazo-5-oxo-norleucinyl]-6-diazo-5-oxo-norleucine against experimental tumors in conventional and nude mice. Cancer Res (1979) 1.14
In vitro stem cell assay in head and neck squamous carcinoma. Am J Surg (1980) 1.14
In vitro antitumor activity of the novel marine agent, ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients. Ann Oncol (1998) 1.14
Protein-associated DNA breaks in cells treated with adriamycin or ellipticine. Biochim Biophys Acta (1978) 1.13
A bioavailability and pharmacokinetic study of oral and intravenous hydroxyurea. Blood (1998) 1.13
Irinotecan is active in chemonaive patients with metastatic gastric cancer: a phase II multicentric trial. Br J Cancer (2003) 1.12
Cancer patient expectations of and communication with oncologists and oncology nurses: the experience of an integrated oncology and palliative care service. Support Care Cancer (2000) 1.12
Camptothecins: a review of their development and schedules of administration. Eur J Cancer (1998) 1.12
ESMO takes a stand on supportive and palliative care. Ann Oncol (2003) 1.12
Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies. Eur J Cancer (2012) 1.11
Lysozymuria and renal tubular dysfunction in monocytic and myelomonocytic leukemia. Am J Med (1969) 1.11
Double minute chromosomes and homogeneously staining regions in tumors taken directly from patients versus in human tumor cell lines. Anticancer Drugs (1991) 1.11
Assessment of in vitro drug sensitivity of human tumor cells using [3H]thymidine incorporation in a modified human tumor stem cell assay. Cancer Res (1982) 1.11
Role of complement activation in hypersensitivity reactions to doxil and hynic PEG liposomes: experimental and clinical studies. J Liposome Res (2003) 1.11
Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies. J Clin Oncol (1999) 1.11
Telomere-interactive agents affect proliferation rates and induce chromosomal destabilization in sea urchin embryos. Anticancer Drug Des (1999) 1.11
5-Azacytidine. A new anticancer drug with effectiveness in acute myelogenous leukemia. Ann Intern Med (1976) 1.10
Hypercalcemia associated with neoplastic disease. Ann Intern Med (1970) 1.10
Human tumor cloning: feasibility and clinical correlations. Cancer Chemother Pharmacol (1981) 1.10
Measure once or twice -- does it really matter? J Natl Cancer Inst (1999) 1.09
Doxorubicin-polymer conjugates: further demonstration of the concept of enhanced permeability and retention. Clin Cancer Res (1999) 1.09
Progressive paresthesias after cessation of therapy with very high-dose cisplatin. Cancer Chemother Pharmacol (1989) 1.08
Mitoxantrone in epithelial carcinoma of the ovary. A Southwest Oncology Group study. Am J Clin Oncol (1984) 1.08
Platinum-DNA damage in leukocyte DNA of patients receiving carboplatin and cisplatin chemotherapy, measured by atomic absorption spectrometry. Carcinogenesis (1991) 1.08
Challenges posed by non-random missing quality of life data in an advanced-stage colorectal cancer clinical trial. Psychooncology (2000) 1.08